Medicine developed in collaboration between Boehringer Ingelheim and Eli Lilly.
Boehringer Ingelheim and Eli Lilly and Company have announced that Jardiance, a treatment for adults with chronic kidney disease (CKD), has been approved by the European Commission (EC). Based on results from SGLT2 inhibitor trial empa-kidney, the study found Jardiance reduced the risk of kidney disease progression or cardiovascular death by 28 percent, with a risk reduction of in hospitalization for any cause by 14 percent.
“Living with chronic kidney disease can have a drastic impact on patients and their family’s lives. CKD not only affects individuals but also society overall due to the high economic burden to healthcare systems,” said Carinne Brouillon, head of human pharma, Boehringer Ingelheim, in a company press release. “As we deepen our knowledge in interconnected cardio-renal-metabolic conditions, we are very excited about the approval and the potential for empagliflozin to play an essential role in helping patients, their physicians and healthcare systems.”
Reference: Jardiance® (empagliflozin) approved in the EU for the treatment of adults with chronic kidney disease. Business Wire. July 25, 2023. Accessed July 26, 2023. https://www.businesswire.com/news/home/20230718878355/en/Jardiance%C2%AE-empagliflozin-approved-in-the-EU-for-the-treatment-of-adults-with-chronic-kidney-disease
#European #Commission #Approves #Chronic #Kidney #Disease #Treatment #Jardiance